Pegfilgrastim Biosimilar Market
Pegfilgrastim biosimilar Market Analysis Report By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies), By Region - Global Market Insights 2020-2026
Analysis of Pegfilgrastim Biosimilar market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Product Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.2. Forecast Factors - Relevance & Impact 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 5. COVID19 Crisis Analysis 5.1.1. Current COVID19 Statistics and Probable Future Impact 5.1.2. COVID-19 Impact on GDP 5.1.3. COVID-19 Impact of Pegfilgrastim Biosimilar Market 6. Market Context 6.1. Product Development 6.2. Product Adoption / Usage Analysis 6.3. Regulatory Scenario 6.4. Pipeline Assessment 7. Global Pegfilgrastim Biosimilar Market Value Analysis 2018-2019 and Forecast, 2019-2026 7.1. Historical Market Value (US$ Mn) Analysis, 2018-2019 7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2026 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026, by Distributional Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Distributional Channel, 2018-2019 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distributional Channel, 2020-2026 8.3.1. Hospital pharmacies 8.3.2. Retail pharmacies 8.3.3. Mail-Order pharmacies 8.4. Market Attractiveness Analysis By Distributional Channel 9. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026, by Region 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2019 9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2026 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. East Asia 9.3.5. South Asia 9.3.6. Oceania 9.3.7. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 10.3.1. By Country 10.3.1.1. U.S. 10.3.1.2. Canada 10.3.2. By Application 10.3.3. By Distributional Channel 10.4. Market Attractiveness Analysis 10.5. Key Market Participants - Intensity Mapping 10.6. Drivers and Restraints - Impact Analysis 11. Latin America Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 11.3.1. By Country 11.3.1.1. Brazil 11.3.1.2. Mexico 11.3.1.3. Argentina 11.3.1.4. Rest of Latin America 11.3.2. By Application 11.3.3. By Distributional Channel 11.4. Market Attractiveness Analysis 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 12. Europe Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 12.3.1. By Country 12.3.1.1. Germany 12.3.1.2. Italy 12.3.1.3. France 12.3.1.4. U.K. 12.3.1.5. Spain 12.3.1.6. Russia 12.3.1.7. Rest of Europe 12.3.2. By Application 12.3.3. By Distributional Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. South Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 13.3.1. By Country 13.3.1.1. India 13.3.1.2. Thailand 13.3.1.3. Indonesia 13.3.1.4. Malaysia 13.3.1.5. Rest of South Asia 13.3.2. By Application 13.3.3. By Distributional Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. East Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Application 14.3.3. By Distributional Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Oceania Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 15.3.1. By Country 15.3.1.1. Australia 15.3.1.2. New Zealand 15.3.2. By Application 15.3.3. By Distributional Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Pegfilgrastim Biosimilar Market Analysis 2018-2019 and Forecast 2020-2026 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Application 16.3.3. By Distributional Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Concentration 17.3. Market Share Analysis of Top Players 17.4. Market Presence Analysis 17.4.1. By Regional footprint of Players 17.4.2. Product foot print by Players 17.4.3. Channel Foot Print by Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. Mylan NV 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Analyst Commentary 18.3.1.4. Key Financials 18.3.1.5. Recent Developments 18.3.1.6. Sales Footprint 18.3.1.7. Strategy Overview 18.3.1.7.1. Marketing Strategy 18.3.1.7.2. Product Strategy 18.3.1.7.3. Channel Strategy 18.3.2. Novartis AG 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Analyst Commentary 18.3.2.4. Key Financials 18.3.2.5. Recent Developments 18.3.2.6. Sales Footprint 18.3.2.7. Strategy Overview 18.3.2.7.1. Marketing Strategy 18.3.2.7.2. Product Strategy 18.3.2.7.3. Channel Strategy 18.3.3. Coherus BioSciences 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Analyst Commentary 18.3.3.4. Key Financials 18.3.3.5. Recent Developments 18.3.3.6. Sales Footprint 18.3.3.7. Strategy Overview 18.3.3.7.1. Marketing Strategy 18.3.3.7.2. Product Strategy 18.3.3.7.3. Channel Strategy 18.3.4. Mundipharma International 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Analyst Commentary 18.3.4.4. Key Financials 18.3.4.5. Recent Developments 18.3.4.6. Sales Footprint 18.3.4.7. Strategy Overview 18.3.4.7.1. Marketing Strategy 18.3.4.7.2. Product Strategy 18.3.4.7.3. Channel Strategy 18.3.5. Biocon 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Analyst Commentary 18.3.5.4. Key Financials 18.3.5.5. Recent Developments 18.3.5.6. Sales Footprint 18.3.5.7. Strategy Overview 18.3.5.7.1. Marketing Strategy 18.3.5.7.2. Product Strategy 18.3.5.7.3. Channel Strategy 18.3.6. Intas Pharmaceuticals Ltd. 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Analyst Commentary 18.3.6.4. Key Financials 18.3.6.5. Recent Developments 18.3.6.6. Sales Footprint 18.3.6.7. Strategy Overview 18.3.6.7.1. Marketing Strategy 18.3.6.7.2. Product Strategy 18.3.6.7.3. Channel Strategy 18.3.7. Pfizer Inc. 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Analyst Commentary 18.3.7.4. Key Financials 18.3.7.5. Recent Developments 18.3.7.6. Sales Footprint 18.3.7.7. Strategy Overview 18.3.7.7.1. Marketing Strategy 18.3.7.7.2. Product Strategy 18.3.7.7.3. Channel Strategy 18.3.8. Dr Reddy’s Laboratories 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Analyst Commentary 18.3.8.4. Key Financials 18.3.8.5. Recent Developments 18.3.8.6. Sales Footprint 18.3.8.7. Strategy Overview 18.3.8.7.1. Marketing Strategy 18.3.8.7.2. Product Strategy 18.3.8.7.3. Channel Strategy 18.3.9. Zydus Cadila 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Analyst Commentary 18.3.9.4. Key Financials 18.3.9.5. Recent Developments 18.3.9.6. Sales Footprint 18.3.9.7. Strategy Overview 18.3.9.7.1. Marketing Strategy 18.3.9.7.2. Product Strategy 18.3.9.7.3. Channel Strategy 18.3.10. Apotex Inc. 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Analyst Commentary 18.3.10.4. Key Financials 18.3.10.5. Recent Developments 18.3.10.6. Sales Footprint 18.3.10.7. Strategy Overview 18.3.10.7.1. Marketing Strategy 18.3.10.7.2. Product Strategy 18.3.10.7.3. Channel Strategy 18.3.11. Emcure Pharmaceuticals Pvt Ltd. 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Analyst Commentary 18.3.11.4. Key Financials 18.3.11.5. Recent Developments 18.3.11.6. Sales Footprint 18.3.11.7. Strategy Overview 18.3.11.7.1. Marketing Strategy 18.3.11.7.2. Product Strategy 18.3.11.7.3. Channel Strategy 18.3.12. USV Private Limited 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Analyst Commentary 18.3.12.4. Key Financials 18.3.12.5. Recent Developments 18.3.12.6. Sales Footprint 18.3.12.7. Strategy Overview 18.3.12.7.1. Marketing Strategy 18.3.12.7.2. Product Strategy 18.3.12.7.3. Channel Strategy 18.3.13. Lupin 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Analyst Commentary 18.3.13.4. Key Financials 18.3.13.5. Recent Developments 18.3.13.6. Sales Footprint 18.3.13.7. Strategy Overview 18.3.13.7.1. Marketing Strategy 18.3.13.7.2. Product Strategy 18.3.13.7.3. Channel Strategy 18.3.14. Kashiv Biosciences 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Analyst Commentary 18.3.14.4. Key Financials 18.3.14.5. Recent Developments 18.3.14.6. Sales Footprint 18.3.14.7. Strategy Overview 18.3.14.7.1. Marketing Strategy 18.3.14.7.2. Product Strategy 18.3.14.7.3. Channel Strategy 18.3.15. Fresenius Kabi 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Analyst Commentary 18.3.15.4. Key Financials 18.3.15.5. Recent Developments 18.3.15.6. Sales Footprint 18.3.15.7. Strategy Overview 18.3.15.7.1. Marketing Strategy 18.3.15.7.2. Product Strategy 18.3.15.7.3. Channel Strategy 18.3.16. Green Cross Corp 18.3.16.1. Overview 18.3.16.2. Product Portfolio 18.3.16.3. Analyst Commentary 18.3.16.4. Key Financials 18.3.16.5. Recent Developments 18.3.16.6. Sales Footprint 18.3.16.7. Strategy Overview 18.3.16.7.1. Marketing Strategy 18.3.16.7.2. Product Strategy 18.3.16.7.3. Channel Strategy 18.3.17. Jiangsu Hengrui Medicine Co., Ltd 18.3.17.1. Overview 18.3.17.2. Product Portfolio 18.3.17.3. Analyst Commentary 18.3.17.4. Key Financials 18.3.17.5. Recent Developments 18.3.17.6. Sales Footprint 18.3.17.7. Strategy Overview 18.3.17.7.1. Marketing Strategy 18.3.17.7.2. Product Strategy 18.3.17.7.3. Channel Strategy 19. Assumptions and Acronyms Used 20. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 02: Global Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Region
Table 03: North America Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 04: North America Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 05: Latin America Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 06: Latin America Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 07: Europe Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 08: Europe Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 09: South Asia Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 10: South Asia Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 11: East Asia Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 12: East Asia Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 13: Oceania Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 14: Oceania Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
Table 15: Middle East and Africa Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Distribution Channel
Table 16: Middle East and Africa Pegfilgrastim Biosimilar Market Size (US$ Mn) Analysis 2018-2019 and Forecast 2019-2026, By Country
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Pegfilgrastim Biosimilar Market Historical Market Value (US$ Mn) Analysis, 2018-2019
Figure 02: Global Pegfilgrastim Biosimilar Current and Future Market Value (US$ Mn), 2019-2026 & Y-o-Y Growth Trend
Figure 03: Pegfilgrastim Biosimilar Market Absolute $ Opportunity, 2019-2026
Figure 04: Global Pegfilgrastim Biosimilar Market Share Analysis (%) By Distribution Channel, 2020 & 2026
Figure 05: Global Pegfilgrastim Biosimilar Market Y-o-Y Growth (%) By Distribution Channel, 2020-2026
Figure 06: Global Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 07: Global Pegfilgrastim Biosimilar Market Share Analysis (%) By Region, 2020 & 2026
Figure 08: Global Pegfilgrastim Biosimilar Market Y-o-Y Growth (%) By Region, 2019-2026
Figure 09: Global Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Region
Figure 10: North America Pegfilgrastim Biosimilar Market Share, By Country (2019)
Figure 11: North America Pegfilgrastim Biosimilar Market Share, By Distribution channel (2019)
Figure 12: North America Pegfilgrastim Biosimilar Market Value (US$ Mn) Analysis, 2018-2019
Figure 13: North America Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 14: North America Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 15: North America Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 16: Latin America Pegfilgrastim Biosimilar Market Share, By Country (2020)
Figure 17: Latin America Pegfilgrastim Biosimilar Market Share, By Distribution channel (2020)
Figure 18: Latin America Pegfilgrastim Biosimilar Market Value (US$ Mn) Analysis, 2018-2019
Figure 19: Latin America Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 20: Latin America Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 21: Latin America Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 22: Europe Pegfilgrastim Biosimilar Market Share, By Country (2019)
Figure 23: Europe Pegfilgrastim Biosimilar Market Share, By Distribution channel (2019)
Figure 24: Europe Pegfilgrastim Biosimilar Market Value (US$ Mn) Analysis, 2018-2019
Figure 25: Europe Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 26: Europe Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 27: Europe Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 28: South Asia Pegfilgrastim Biosimilar Market Share, By Country (2019)
Figure 29: South Asia Pegfilgrastim Biosimilar Market Share, By Distribution channel (2020)
Figure 30: South Asia Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 31: South Asia Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 32: South Asia Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 33: East Asia Pegfilgrastim Biosimilar Market Share, By Country (2019)
Figure 34: East Asia Pegfilgrastim Biosimilar Market Share, By Distribution channel (2019)
Figure 35: East Asia Pegfilgrastim Biosimilar Market Value (US$ Mn) Analysis, 2018-2019
Figure 36: East Asia Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 37: East Asia Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 38: East Asia Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 39: Oceania Pegfilgrastim Biosimilar Market Share, By Country (2020)
Figure 40: Oceania Pegfilgrastim Biosimilar Market Share, By Distribution channel (2020)
Figure 41: Oceania Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 42: Oceania Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 43: Oceania Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Figure 44: Middle East and Africa Pegfilgrastim Biosimilar Market Share, By Country (2021)
Figure 45: Middle East and Africa Pegfilgrastim Biosimilar Market Share, By Distribution channel (2021)
Figure 46: Middle East and Africa Pegfilgrastim Biosimilar Market Value (US$ Mn) Analysis, 2018-2019
Figure 47: Middle East and Africa Pegfilgrastim Biosimilar Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026
Figure 48: Middle East and Africa Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Country
Figure 49: Middle East and Africa Pegfilgrastim Biosimilar Market Attractiveness Analysis, By Distribution Channel
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Pegfilgrastim Biosimilar Market
*Mail attachment includes 49 figures & 16 tables